SureTrader
Home > Boards > US Listed > Biotechs >

Bristol-Myers (BMY)

BMY RSS Feed
Add BMY Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 1/22/2018 2:22:28 PM - Followers: 34 - Board type: Free - Posts Today: 0
SureTrader
BMY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BMY News: European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years & Olde... 01/22/2018 06:59:00 AM
BMY News: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with... 01/20/2018 02:03:00 PM
BMY News: Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Mye... 01/08/2018 08:30:00 AM
BMY News: Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference 01/03/2018 09:00:00 AM
BMY News: Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Me... 12/20/2017 03:28:00 PM
News News Alert: European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years & Olde... 01/22/2018 06:59:00 AM
PostSubject
#678  Sticky Note BMY’s 3Q17 PR: DewDiligence 10/26/17 11:21:07 AM
#735   Interesting news on Keytruda. Celgene making another potential Johnny_C 01/17/18 07:28:19 AM
#734   BMY -2% on Keytruda news: #msg-137706298. DewDiligence 01/16/18 09:34:54 AM
#733   True, got a little burst at close. Some Johnny_C 01/11/18 04:06:55 PM
#732   The mystery wrt the 4Q17 CC schedule remains. DewDiligence 01/10/18 03:53:09 PM
#731   The transcript is really a love fest with Johnny_C 01/10/18 03:48:52 PM
#730   BMY JPM slides: DewDiligence 01/09/18 12:17:10 PM
#729   Here's Hoping.... otherwise I am down a 2018 Johnny_C 12/27/17 11:39:47 AM
#728   PFE has reported after BMY every quarter during DewDiligence 12/27/17 10:52:27 AM
#727   PFE earnings the 30th. Usually they are Johnny_C 12/27/17 10:46:30 AM
#726   Roger that :) Mostly invested Johnny_C 12/19/17 01:49:38 PM
#725   LOL, that's pretty funny. DewDiligence 12/19/17 01:07:27 PM
#724   I thought that tweet was funny so I Johnny_C 12/19/17 01:03:15 PM
#723   I consider pharma/biotech to be one industry. My DewDiligence 12/19/17 12:57:23 PM
#722   Thanks, I love conspiracies... After having big win Johnny_C 12/19/17 12:50:25 PM
#721   https://twitter.com/DewDiligence/status/943168656422375424 :- ) DewDiligence 12/19/17 12:19:47 PM
#720   Feb 5 earnings call. Will certainly be intersting Johnny_C 12/19/17 12:10:38 PM
#719   https://www.fiercepharma.com/marketing/pfizer-bms-eliquis-takes-j-j-s-next-gen-anticoagulant-market- Johnny_C 12/18/17 04:34:50 PM
#718   I know... Even if a mega deal was Johnny_C 12/18/17 01:58:37 PM
#717   PFE's $10B buyback is just an authorization—there is DewDiligence 12/18/17 01:51:29 PM
#716   BMY and PFE raising dividends, PFE doing a Johnny_C 12/18/17 01:13:06 PM
#715   Looks like big Pharma / multi nationals have DewDiligence 12/18/17 09:35:45 AM
#714   Looks like big Pharma / multi nationals have Johnny_C 12/18/17 08:59:38 AM
#713   Sabby Management has a ton of BMY, as Johnny_C 12/14/17 07:56:20 PM
#712   No, and more calls expiring worthless tomorrow. Johnny_C 12/14/17 08:29:42 AM
#711   PDUFA date for Opdivo/Yervoy in first-line RCC is DewDiligence 12/13/17 07:47:03 PM
#710   The small dividend increase doesn't say anything in DewDiligence 12/08/17 08:52:22 AM
#709   Might be wrong but that doesn’t seem to Johnny_C 12/07/17 10:47:29 PM
#708   BMY increases annualized dividend to $1.60 (from $1.56): DewDiligence 12/07/17 05:39:10 PM
#707   Intersting, according to latest interview by BMY they Johnny_C 12/07/17 11:55:00 AM
#706   Yes, it is, especially for cancer treatments. DewDiligence 12/06/17 10:23:59 AM
#705   China market is huge! Johnny_C 12/06/17 10:19:03 AM
#704   Breakthrough on HIV? Opdivo the cure? Stock Barber 12/01/17 12:46:50 PM
#703   Opdivo shows OS benefit in Chinese NSCLC second-line patients: DewDiligence 11/30/17 07:21:28 PM
#702   It's going to the trash can rather than DewDiligence 11/22/17 03:12:31 PM
#701   Sure doesn't bode well. Looks like the pps chmcnfunds 11/22/17 03:09:02 PM
#700   (IPH.PA)—BMY licensed program bites the dust: #msg-136389492. DewDiligence 11/22/17 12:23:41 PM
#699   Hmmm. Looks like non of the Johnny_C 11/20/17 05:20:55 PM
#698   The BD comments were interesting. I am going Johnny_C 11/16/17 08:58:28 PM
#697   Very good presentation by John Elicker, who must DewDiligence 11/15/17 03:52:01 PM
#696   Seeking Alpha transcript! https://seekingalpha.com/article/4125170-bristol-mye Johnny_C 11/15/17 03:51:06 PM
#695   Interesting trading.... mostly all red except Pfe Johnny_C 11/14/17 11:16:57 PM
#694   Interesting choice naming COO. Very experienced in oncology Johnny_C 11/14/17 07:16:41 AM
#693   Yes and no. Clinical trials very Johnny_C 11/13/17 01:05:36 PM
#692   Oncology can't be anywhere near 50% of PFE's DewDiligence 11/13/17 10:59:35 AM
#691   COO named at PFE after a very long Johnny_C 11/13/17 10:23:39 AM
#690   https://seekingalpha.com/article/4124190-bristol-myers-squibb-brings-ace-card-mi Inoviorulez 11/13/17 09:20:52 AM
#689   Nice, here we go again. Big move up Johnny_C 11/08/17 03:52:16 PM
#688   BMY presents OS data from successful CHECKPOINT-214 study DewDiligence 11/07/17 11:31:45 AM
#687   Tony, if in fact they are a buy Johnny_C 11/06/17 10:06:20 AM
#686   Hey Tony, this is quite elaborate. mbenson898 11/02/17 09:52:36 AM
PostSubject